Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy

被引:98
作者
Boeluekbas, Servet [1 ]
Manegold, Christian [2 ]
Eberlein, Michael [3 ]
Bergmann, Thomas [1 ]
Fisseler-Eckhoff, Annette [4 ,5 ]
Schirren, Joachim [1 ]
机构
[1] Dr Horst Schmidt Klin, Dept Thorac Surg, D-65199 Wiesbaden, Germany
[2] Heidelberg Univ, Univ Med Ctr Mannheim, D-6800 Mannheim, Germany
[3] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD USA
[4] Dr Horst Schmidt Klin, Inst Pathol, D-65199 Wiesbaden, Germany
[5] Dr Horst Schmidt Klin, Inst Cytol, D-65199 Wiesbaden, Germany
关键词
Malignant pleural mesothelioma; Radical pleurectomy; Surgery; Radiation; Chemotherapy; DOSE HEMITHORACIC RADIATION; PEMETREXED PLUS CISPLATIN; PHASE-II TRIAL; EXTRAPLEURAL PNEUMONECTOMY; MULTIMODALITY THERAPY; SURGICAL-MANAGEMENT; PLEURECTOMY/DECORTICATION; RESECTION; PREVENTION; SURGERY;
D O I
10.1016/j.lungcan.2009.08.019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: The role of surgery in the management of malignant pleural mesothelioma (MPM) is controversial and there are no established guidelines. We describe the feasibility and long-term outcomes associated with Radical Pleurectomy (RP) as surgical therapy modality in a standardized trimodality therapy concept of MPM. Methods: From November 2002 to October 2007, 35 out of 102 consecutive patients with MPM were enrolled in our prospective database. They underwent trimodality therapy, including RP followed by 4 cycles of chemotherapy with Cisplatin (75 mg/m(2))/Pemetrexed (500 mg/m(2)) and radiotherapy 4-6 weeks after operation. Results: Median age was 65 years. Nineteen patients were in advanced stages III and IV (54.3%). Tumor histology was epithelial in 27 patients (77.1%). Macroscopic complete resection could be achieved in 18 patients (51.4%). Surgical morbidity/mortality and trimodality treatment-related mortality were 20.0%, 2.9% and 5.8%, respectively. Thirty-three patients completed the trimodality therapy. Median follow-up was 21.7 months. Overall median survival was 30.0 months. One-, 2-, and 3-year-survival were 69%, 50% and 31%, respectively. Advanced stages III/IV (p=0.06), macroscopic incomplete resections (p=0.001), non-epithelial histology (p=0.55) and nodal metastases (p=0.19) were associated with poorer survival. Conclusions: The trimodality therapy concept with RP demonstrates promising results in terms of long-term survival, morbidity and mortality. We propose that a surgical philosophy of limiting the procedure related morbidity while achieving comparable cytoreductive results allows patients to maintain physiological reserve to be eligible for multimodality treatment options in the long-term. The observed and theoretical benefits of this trimodality treatment approach warrant confirmation in larger RCT. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:75 / 81
页数:7
相关论文
共 27 条
[1]  
Averbach A M, 1996, Cancer Treat Res, V81, P193
[2]   PREVENTION OF MALIGNANT SEEDING AFTER INVASIVE DIAGNOSTIC PROCEDURES IN PATIENTS WITH PLEURAL MESOTHELIOMA - A RANDOMIZED TRIAL OF LOCAL RADIOTHERAPY [J].
BOUTIN, C ;
REY, F ;
VIALLAT, JR .
CHEST, 1995, 108 (03) :754-758
[3]   DIAGNOSTIC AND THERAPEUTIC STRATEGY IN MALIGNANT PLEURAL MESOTHELIOMA [J].
BRANSCHEID, D ;
KRYSA, S ;
BAUER, E ;
BULZEBRUCK, H ;
SCHIRREN, J .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1991, 5 (09) :466-473
[4]   PLEUROPNEUMONECTOMY IN MANAGEMENT OF DIFFUSE MALIGNANT MESOTHELIOMA OF PLEURA - EXPERIENCE WITH 29 PATIENTS [J].
BUTCHART, EG ;
ASHCROFT, T ;
BARNSLEY, WC ;
HOLDEN, MP .
THORAX, 1976, 31 (01) :15-24
[5]   Trimodality Therapy With Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural Mesothelioma [J].
de Perrot, Marc ;
Feld, Ronald ;
Cho, B. C. John ;
Bezjak, Andrea ;
Anraku, Masaki ;
Burkes, Ronald ;
Roberts, Heidi ;
Tsao, Ming S. ;
Leighl, Natasha ;
Keshavjee, Shaf ;
Johnston, Michael R. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1413-1418
[6]   Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients [J].
Flores, Raja M. ;
Pass, Harvey I. ;
Seshan, Venkatraman E. ;
Dycoco, Joseph ;
Zakowski, Maureen ;
Carbone, Michele ;
Bains, Manjit S. ;
Rusch, Valerie W. .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2008, 135 (03) :620-+
[7]   Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma [J].
Gupta, V ;
Mychalczak, B ;
Krug, L ;
Flores, R ;
Bains, M ;
Rusch, VW ;
Rosenzweig, KE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (04) :1045-1052
[8]   Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma [J].
Krug, Lee M. ;
Pass, Harvey I. ;
Rusch, Valerie W. ;
Kindler, Hedy L. ;
Sugarbaker, David J. ;
rosenzweig, Kenneth E. ;
Flores, Raja ;
Friedberg, Joseph S. ;
Pisters, Katherine ;
Monberg, Matthew ;
Obasaju, Coleman K. ;
Vogelzang, Nicholas J. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) :3007-3013
[9]   Prophylactic radiotherapy to intervention sites in mesothelioma: A systematic review and survey of UK practice [J].
Lee, Caroline ;
Bayman, Neil ;
Swindell, Ric ;
Faivre-Finn, Corinne .
LUNG CANCER, 2009, 66 (02) :150-156
[10]   Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma [J].
Lee, TT ;
Everett, DL ;
Shu, HKG ;
Jahan, TM ;
Roach, M ;
Speight, JL ;
Cameron, RB ;
Phillips, TL ;
Chan, A ;
Jablons, DM .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2002, 124 (06) :1183-1189